Intercept Pharmaceuticals (ICPT) Stock Rating Lowered by ValuEngine

Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Monday.

ICPT has been the topic of several other research reports. Needham & Company LLC reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 2nd. Wedbush reiterated a “buy” rating and issued a $203.00 target price (down previously from $217.00) on shares of Intercept Pharmaceuticals in a report on Friday, August 3rd. BidaskClub lowered shares of Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. Royal Bank of Canada restated a “buy” rating and issued a $115.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. Finally, Goldman Sachs Group upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “buy” rating and raised their price target for the stock from $46.00 to $157.00 in a research report on Monday, August 6th. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Intercept Pharmaceuticals has an average rating of “Buy” and a consensus target price of $140.53.

Shares of ICPT opened at $100.71 on Monday. The firm has a market capitalization of $3.23 billion, a P/E ratio of -7.00 and a beta of -1.08. Intercept Pharmaceuticals has a one year low of $51.05 and a one year high of $133.74. The company has a current ratio of 5.98, a quick ratio of 5.98 and a debt-to-equity ratio of 3.83.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) EPS for the quarter, topping the consensus estimate of ($2.65) by $0.47. The firm had revenue of $47.00 million for the quarter, compared to the consensus estimate of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 645.54%. The business’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter last year, the firm posted ($2.89) EPS. On average, research analysts expect that Intercept Pharmaceuticals will post -10 EPS for the current fiscal year.

In other Intercept Pharmaceuticals news, insider David Shapiro sold 759 shares of the firm’s stock in a transaction on Friday, October 5th. The shares were sold at an average price of $110.65, for a total value of $83,983.35. Following the sale, the insider now directly owns 39,152 shares in the company, valued at approximately $4,332,168.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 11,101 shares of company stock worth $1,177,128 over the last 90 days. Company insiders own 4.90% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Strs Ohio acquired a new stake in shares of Intercept Pharmaceuticals during the 3rd quarter valued at about $126,000. Chicago Equity Partners LLC acquired a new stake in shares of Intercept Pharmaceuticals during the 3rd quarter valued at about $215,000. GWM Advisors LLC acquired a new stake in shares of Intercept Pharmaceuticals during the 3rd quarter valued at about $220,000. Tocqueville Asset Management L.P. acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at about $252,000. Finally, Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at about $264,000. Institutional investors and hedge funds own 69.90% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Featured Story: How to Profit and Limit Losses With Stop Orders

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply